Recent Progress in Characterizing Long Noncoding RNAs in Cancer Drug Resistance

Zhao, Wenyuan; Shan, Bin; He, Dan; Cheng, Yuanda; Li, Bin; Zhang, Chunfang; Duan, Chaojun

doi:10.7150/jca.30877

Cited by 41 publications

(30 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It plays an important roles in many life activities, such as dose compensation, cell cycle regulation, epigenetic regulation, and cell differentiation regulation. 53 It is an emerging regulatory RNA that can be selectively packaged into exosomes and acts as a messenger in intercellular communication to regulate tumor growth, metastasis and angiogenesis, and reshapes the TME. 54,55 For example, lncRNAs-ATB was a novel cancer-related lncRNA that was abnormally expressed in hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer, and lung cancer, and promoting tumorigenesis and development mainly by competitively binding miRNA (miR-200 family) to induce EMT.…”

Section: Contents Of Exosomesmentioning

confidence: 99%

Exosomes: key players in cancer and potential therapeutic strategy

Dai

Zhong

et al. 2020

Sig Transduct Target Ther

644

395

View full text Add to dashboard Cite

Exosomes are extracellular vesicles secreted by most eukaryotic cells and participate in intercellular communication. The components of exosomes, including proteins, DNA, mRNA, microRNA, long noncoding RNA, circular RNA, etc., which play a crucial role in regulating tumor growth, metastasis, and angiogenesis in the process of cancer development, and can be used as a prognostic marker and/or grading basis for tumor patients. Hereby, we mainly summarized as followed: the role of exosome contents in cancer, focusing on proteins and noncoding RNA; the interaction between exosomes and tumor microenvironment; the mechanisms that epithelial-mesenchymal transition, invasion and migration of tumor affected by exosomes; and tumor suppression strategies based on exosomes. Finally, the application potential of exosomes in clinical tumor diagnosis and therapy is prospected, which providing theoretical supports for using exosomes to serve precise tumor treatment in the clinic.

show abstract

Section: Contents Of Exosomesmentioning

confidence: 99%

Exosomes: key players in cancer and potential therapeutic strategy

Dai

Zhong

et al. 2020

Sig Transduct Target Ther

644

395

View full text Add to dashboard Cite

show abstract

“…Resistance to cancer chemotherapy is a major cause of concern. The clinical characteristics of drug-resistant cancer are noticeably different in terms of genetic and molecular profiles [ 26 , 27 , 28 ]. Therefore, to better understand the differences between sensitive and resistant colon cancer cells, we compared HT-29 cells (sensitive) with YUMC-C1 and YUMC-C2 cells (patient-derived resistant and metastatic) after treatment with lenvatinib, oxaliplatin, and their combination both in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis

Lim

Choi

Kim

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer cells can exhibit resistance to different anticancer drugs by acquiring enhanced anti-apoptotic potential, improved DNA injury resistance, diminished enzymatic inactivation, and enhanced permeability, allowing for cell survival. However, the genetic mechanisms for these effects are unknown. Therefore, in this study, we obtained drug-sensitive HT-29 cells (commercially) and drug-resistant cancer cells (derived from biochemically and histologically confirmed colon cancer patients) and performed microarray analysis to identify genetic differences. Cellular proliferation and other properties were determined after treatment with oxaliplatin, lenvatinib, or their combination. In vivo, tumor volume and other properties were examined using a mouse xenograft model. The oxaliplatin and lenvatinib cotreatment group showed more significant cell cycle arrest than the control group and groups treated with either agent alone. Oxaliplatin and lenvatinib cotreatment induced the most significant tumor shrinkage in the xenograft model. Drug-resistant and metastatic colon cancer cells evaded the anticancer drug effects via angiogenesis. These findings present a breakthrough strategy for treating drug-resistant cancer.

show abstract

“…LncRNAs exhibit multiple functions in cancer drug sensitivity and patient prognosis [ [43][44][45]]. We thus reasoned whether the identified lncRNAs mediated by the DNA methylation and transcription factor in our study have impact on drug and prognosis efficiency for colon cancer.…”

Section: Discussionmentioning

confidence: 99%

Dissecting drug and prognostic lncRNA signature mediated by DNA methylation and transcription factor in colon cancer

Zhang¹,

Shen²,

Song³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Colon cancer is still the most commonly diagnosed malignancy and leading cause of death worldwide. Apart from living habits, genetic and epigenetic changes are key factors to influence the risk of colon cancer. However, the impact of epigenetic alterations in non-coding RNAs and the consequences for colon cancer has not been fully characterized.Methods: We detected differential methylation sites (DMSs) in lncRNA promoters, and identified lncQTMs by association test. To investigate TF binding affected by DNA methylation, we characterized known TF motif occurrence among DMSs collected from MEME suit. We further combined methylome and transcriptome data to construct TF-methylation-lncRNA relationships. To study the role of lncRNAs in drug response, we used pharmacological and lncRNA profiles derived from CCLE and predict drug response by lncRNA expression level. We also used the combination of TF-methylation-lncRNA relationship to stratified patient survival information by a risk model.Results: DNA methylation display global hyper-methylation character in lncRNA promoters, and they tend to have negative relationship with the corresponding lncRNAs. Negative lncQTMs located near TSS have more significant and stronger correlation with the corresponding lncRNAs. Some lncRNAs mediated by the interplay between DNA methylation and TFs are proved markers for colon cancer. Typically, lncRNA CAHM, RP11-834C11.4 and LINC00460 are good predictors for 5 drug components (17-AAG, Sorafenib, TKI258, RAF265, Topotecan) in colon cancer. And we found HES1_cg24685006_RP4-728D4.2 and SREBF1_cg05372727_LINC00460 relationships are prognostic signatures for colon cancer.Conclusions: These findings suggested lncRNAs mediated by the interplay between DNA methylation and TFs are promising predictors for drug response, besides, combined TF-methylation-lncRNA can serve as prognostic signature for colon cancer.

show abstract

Recent Progress in Characterizing Long Noncoding RNAs in Cancer Drug Resistance

Cited by 41 publications

References 92 publications

Exosomes: key players in cancer and potential therapeutic strategy

Exosomes: key players in cancer and potential therapeutic strategy

Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis

Dissecting drug and prognostic lncRNA signature mediated by DNA methylation and transcription factor in colon cancer

Contact Info

Product

Resources

About